Our results are in agreement with the study of Janning et al [26], who showed in a small cohort of NSCLC patients treated with PD‐1/PD‐L1 inhibitors that increase in PD‐L1‐positive CTCs was associated with resistance, whereas a decline in PD‐L1‐positive cells was related to response to treatment. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.